Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $132.3 million.

  • Tg Therapeutics' Operating Expenses rose 8523.9% to $132.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $429.1 million, marking a year-over-year increase of 6175.16%. This contributed to the annual value of $287.1 million for FY2024, which is 3475.86% up from last year.
  • Tg Therapeutics' Operating Expenses amounted to $132.3 million in Q3 2025, which was up 8523.9% from $106.3 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Operating Expenses ranged from a high of $132.3 million in Q3 2025 and a low of $35.1 million during Q3 2022
  • In the last 5 years, Tg Therapeutics' Operating Expenses had a median value of $72.7 million in 2024 and averaged $74.9 million.
  • In the last 5 years, Tg Therapeutics' Operating Expenses plummeted by 5977.76% in 2022 and then surged by 8523.9% in 2025.
  • Over the past 5 years, Tg Therapeutics' Operating Expenses (Quarter) stood at $95.3 million in 2021, then decreased by 18.53% to $77.6 million in 2022, then dropped by 27.27% to $56.5 million in 2023, then surged by 38.58% to $78.2 million in 2024, then surged by 69.16% to $132.3 million in 2025.
  • Its Operating Expenses stands at $132.3 million for Q3 2025, versus $106.3 million for Q2 2025 and $112.2 million for Q1 2025.